Psychedelic highlights | January 04 – 08

Shares :

5
(1)
Psychedelic highlights | January 04 – 08

Here is a summary of the news from the last week in the psychedelics market. The value of the psychedelics market is more than $100 billion according to Cannacord most recent report.

Psychedelic market value by company

Last week performance

COMPANYTICKERJAN 08WEEK %
NuminusNUMI$1.26+ 17.7 %
Psyched WellnessPSYC$0.285+ 17.7 %
Mind CureMCUR$0.75+ 2.7 %
MindMedMMED$3.94+ 1.5 %
Red Light HollandsTRIP$0.30– 1.5 %
Revive TherapeuticsRVV$0.60– 3.2 %
CompassCMPS$45.21– 5.1 %
M2Bio SciencesWUHN$0.4010 %
Field TripFTRP$3.75– 10.2 %
Trip TherapeuticsTRYP$0.63– 16 %

Story of the week

1. Psyched Wellness Commences Antioxidant and Anti-Inflammatory Study on Muscimol [news release]

Psyched Wellness  is pleased to share that it has commenced a study to determine the therapeutic values of muscimol for antioxidant and anti-inflammatory purposes via a nerve derived immunity and neuroprotective modulation models.

The study will be led by Brian Tancowny and will focus on determining the effectiveness of the active compound muscimol from the Amanita Muscariamushroom for its potential dual antioxidant and anti-inflammatory properties. 

Read the full news HERE


2. A penny stock in the psychedelic market one step ahead ? [featured]

With a research collaboration and funding agreement with the University of Pretoria, South Africa, M2Bio Sciences is already a step ahead of the competition having already started studying long ago.

Already, several studies have been carried out and have been submitted for review and publication including tests with other magic mushroom species.

Read the full article HERE


3. COMPASS Pathways establishes Centre of Excellence with Sheppard Pratt to accelerate research and improve patient experience in mental health care [news release]

COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health is establishing its first Centre of Excellence in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore, Maryland, United States.

The Centre of Excellence will model the “clinic of the future”, showcasing the best thinking in science, therapy, technology, and design. 

Read the full news HERE


4. Numinus Signs Lab Services Agreement with Optimi Health to Advance Research and Development of Psychedelic Products [news release]

Numinus announced today that it has signed a lab services agreement with Optimi Health Corp. (“Optimi”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, to further the research and development of Canadian-grown psilocybin-producing mushrooms.

“Numinus is an ideal partner to further our research and development of Psilocybemushroom and associated derivatives-based products,” said Mike Stier, CEO, Optimi Health Corp. 

Read the full news HERE


5. Lobe Sciences Announces Changes to Board of Directors [news release]

Lobe Sciences is pleased to announce the appointment of Mr. Michael Petter as an independent director to the Company’s Board of Directors, effective immediately.

Mr. Petter replaces Thomas Baird, who resigned from the Company’s Board of Directors effective today, but still remains CEO of the Company.

Read the full news HERE


6. Mind Cure Announces Build-Out of Digital Therapeutics, iSTRYM: A Technology Platform for Mental Wellness Optimization & Psychedelic Research [news release]

Mind Cure is pleased to announce the release of iSTRYM, the Company’s digital therapeutic tool, designed to provide close to real-time data regarding patient care, procedures and protocols, and other resources for therapists, clinicians, and patients with mental health concerns.

From onboarding patients to collecting critical insights across different arms of the psychedelics research space, iSTRYM could revolutionize the way we build communities around a common goal of mental wellness.” – Geoff Belair, CTO.

Read the full news HERE


7. Field Trip Health Ltd. Announces Participation in a MAPS-sponsored Multi-Site Study of MDMA-Assisted Therapy to Treat Eating Disorders [news release]

Field Trip is pleased to announce it has, subject to completion of a final site inspection, been selected as a trial location for a MAPS-sponsored study on the safety, feasibility and preliminary outcomes of MDMA-assisted therapy to treat eating disorders (the “Eating Disorder Study”), including Anorexia Nervosa.

Anorexia Nervosa is a mental health condition and eating disorder characterized by low weight, food restriction, fear of gaining weight and a strong desire to be thin.

Read the full news HERE


8. Mydecine Innovations Group Shares Intellectual Property Update and Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia [news release]

Mydecine Innovations Group™ announced the filing of seven provisional patent applications with the United States Patent and Trademark Office (USPTO) in its efforts to discover valuable novel compounds in fungi for medicinal and pharmaceutical use.

And more, Mydecine Innovations Group™ announced that it is sponsoring a study titled: “The neurocognitive effects of low dose psychoactive substances,” at Australia’s Macquarie University

Read the full news HERE


9. Nova Mentis Appoints Dr. Kyle Ambert to Scientific Advisory Board [news release]

Nova Mentis Life Science Corp. is pleased to announce that it has appointed Dr. Kyle H. Ambert, PhD to its Scientific Advisory Board, effective immediately. Dr. Ambert has also agreed to become a consultant to NOVA and will assist the Company in designing preclinical and clinical autism spectrum disorder (ASD) studies and analyzing their results.

Read the full news HERE


10. Entheon Biomedical Announces Investment and Business Arrangement with Heading Health LLC [news release]

Entheon is announcing a business arrangement with, and a strategic investment in, Heading Health, LLC (“Heading Health”), a psychiatric clinic platform focused on the administration of psychedelic-assisted therapy to treat mental health disorders.

Entheon has participated in a Series A Preferred Stock Financing, investing $200,000 USD for a 5% stake in Heading Health.

Read the full news HERE


11. Leading Microbiologist, Dr. Robert E.W. Hancock Appointed as Executive Chairman of Core One Labs [news release]

Core One Labs is pleased to announce the appointment of Dr. Robert E.W. Hancock as Executive Chairman of the Company, effective January 6, 2021.

Dr. Hancock is an internationally renowned academic in Microbiology and Immunology – having bestowed upon him the title of UBC Killam Professor of Microbiology and Immunology – is the Director of the University of British Columbia’s R.E.W Hancock Laboratory 

Read the full news HERE


12. Tryp Therapeutics Appoints Dr. William K. Schmidt to Its Scientific Advisory Board [news release]

Try Therapeutics announced today it has appointed Dr. William K. Schmidt, a noted authority in the development of pain drugs, as a Scientific Advisory Board member. Dr. Schmidt, will aid Tryp in the development of its product candidate TRP-8802 for fibromyalgia and other chronic pain conditions.

Read the full news HERE


Sign up for MORE news updates !


This article is written and published by The Cannabis Stock


Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies

The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.

Click on a star to rate this article !

Average rating 5 / 5. Vote count: 1

No votes so far! Be the first to rate this post.


Shares :